poly(A) specific ribonuclease subunit PAN3Genealiases: []
Q-omics provides the consensus-scored PAN3 profile across patient tissues and cancer cell-line models. PAN3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PAN3 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, PAN3 RNA expression shows 21,530 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, COAD, and UVM as cancer lineages where PAN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAN3 survival associations across molecular data types. PAN3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAN3 RNA expression–survival associations across cancer types. High PAN3 expression shows unfavorable associations in ACC, LGG and UVM, but favorable associations in BRCA, SCLC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify ACC as the clearest survival context for PAN3 RNA expression.
This table summarizes PAN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PAN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAN3 shows lower tumor expression in KICH, THCA and UCEC and higher tumor expression in COAD, STAD and CHOL. The COAD box plot shows higher PAN3 RNA expression in tumor versus normal tissue (log2 FC = +1.038, t-test p < 0.001).
This table shows molecular features associated with PAN3 in patient tissues and cancer cell lines. In patient samples, PAN3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PAN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
